Pfizer Wins FDA Nod to Expand Label for Braftovi + Mektovi in Lung Cancer

seekingalpha2023-10-13

Pfizer announced Thursday that the U.S. FDA approved its marketing application to expand the label for its kinase inhibitors Braftovi (encorafenib) + Mektovi (binimetinib) for a group of lung cancer ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2375958918?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-10-13 17:16","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2375958918","market":"us","top_or_hot":-1,"title":"Pfizer Wins FDA Nod to Expand Label for Braftovi + Mektovi in Lung Cancer","media":"seekingalpha","content":"<div>\n<p>Pfizer announced Thursday that the U.S. FDA approved its marketing application to expand the label for its kinase inhibitors Braftovi (encorafenib) + Mektovi (binimetinib) for a group of lung cancer ...</p>\n\n<a href=\"https://seekingalpha.com/news/4020127-pfizer-expands-braftovi-mektovi-lung-cancer\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Wins FDA Nod to Expand Label for Braftovi + Mektovi in Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Wins FDA Nod to Expand Label for Braftovi + Mektovi in Lung Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-13 17:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4020127-pfizer-expands-braftovi-mektovi-lung-cancer><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer announced Thursday that the U.S. FDA approved its marketing application to expand the label for its kinase inhibitors Braftovi (encorafenib) + Mektovi (binimetinib) for a group of lung cancer ...</p>\n\n<a href=\"https://seekingalpha.com/news/4020127-pfizer-expands-braftovi-mektovi-lung-cancer\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://seekingalpha.com/news/4020127-pfizer-expands-braftovi-mektovi-lung-cancer","article_id":"2375958918","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2375958918","pubTimestamp":1697188574,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Pfizer  announced Thursday that the U.S. FDA approved its marketing application to expand the label for its kinase inhibitors Braftovi  + Mektovi  for a group of lung cancer patients with a particular genetic mutation. Accordingly, Braftovi + Mektovi will be allowed as a new personalized treatment for adults whose metastatic non-small cell lung cancer  indicates a BRAF V600E mutation, as confirmed by an FDA-approved test.  The FDA first approved the therapeutic combo in 2018 for certain patients with melanoma harboring the BRAF V600E or V600K mutation. The latest approval is based on data from an ongoing Phase 2 trial called PHAROS, which met both efficacy outcome measures of objective response rate and duration of response in patients with BRAF V600E-mutant metastatic NSCLC.    More on Pfizer  Pfizer: Sell-Off Overdone, Healthy Pipeline To Sustain Above 15% ROE Pfizer Inc.  CEO Albert Bourla Presents at Cantor Fitzgerald Annual Global Health Conference  Pfizer: Protracted Selloff Make","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞"},"translate_title":"辉瑞赢得FDA批准扩大Braftovi+Mektovi在肺癌中的标签","themeId":"c5bbfdf5f7964880af97c1d6f417052c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1},"content_text":"Pfizer announced Thursday that the U.S. FDA approved its marketing application to expand the label for its kinase inhibitors Braftovi (encorafenib) + Mektovi (binimetinib) for a group of lung cancer patients with a particular genetic mutation.Accordingly, Braftovi + Mektovi will be allowed as a new personalized treatment for adults whose metastatic non-small cell lung cancer (NSCLC) indicates a BRAF V600E mutation, as confirmed by an FDA-approved test.The FDA first approved the therapeutic combo in 2018 for certain patients with melanoma harboring the BRAF V600E or V600K mutation.The latest approval is based on data from an ongoing Phase 2 trial called PHAROS, which met both efficacy outcome measures of objective response rate and duration of response in patients with BRAF V600E-mutant metastatic NSCLC.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2375958918"}